US · Healthcare · Drug Manufacturers - General
EPS came in at -0.07 against a street estimate of -0.21 — a beat of 66.7%.
Analysts rate Amarin Corporation PLC a sell (0 buy, 0 hold, 2 sell out of 2) with an average price target of $12.50.
| Fund | Stake |
|---|---|
| Sarissa Capital Management LP | 7.92% |
| Acadian Asset Management LLC | 3.41% |
| Kynam Capital Management, LP | 2.52% |
| Morgan Stanley - Brokerage Accounts | 1.06% |
| Waterfront Wealth Inc. | 1.01% |
| Brooklands Fund Management Limited | 0.84% |
| Eversept Partners, LP | 0.69% |
| Millennium Management LLC | 0.55% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Amarin Corporation PLC — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.